Regenxbio Inc (RGNX)

Days of sales outstanding (DSO)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Receivables turnover		3.45	3.19	3.87	4.76	3.19	12.16	11.32	16.02	13.77	2.93	6.20	6.66	6.30	2.14	2.22	1.60	1.16	3.83	5.67	10.39
DSO	days	105.72	114.28	94.21	76.69	114.56	30.02	32.24	22.79	26.51	124.66	58.83	54.80	57.89	170.51	164.24	228.39	313.50	95.32	64.41	35.12

December 31, 2023 calculation

DSO = 365 ÷ Receivables turnover
= 365 ÷ 3.45
= 105.72

To analyze Regenxbio Inc's days of sales outstanding (DSO) over the past eight quarters, we observe fluctuations in DSO values. The trend shows an overall increase from Q1 2022 to Q3 2023, indicating a potential deterioration in the company's collection efficiency.

The DSO increased from 20.82 days in Q1 2022 to 103.00 days in Q3 2023, peaking in Q3 2023. This substantial rise suggests a lengthening of the average number of days it takes for Regenxbio Inc to collect its accounts receivable, which could lead to cash flow challenges and potential liquidity issues.

Notably, the DSO in the last two quarters of 2022 (Q3 and Q4) was significantly lower than in the first two quarters of 2022 (Q1 and Q2), indicating improved collection efficiency during that period. However, the sharp increase in DSO from Q3 2022 to Q1 2023 suggests a reversal of this trend.

Overall, the increasing trend in DSO warrants further investigation into Regenxbio Inc's credit policies, billing practices, and customer payment behavior to identify potential issues and implement strategies for improving cash flow management and financial performance.